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Sera of patients with paraneoplastic pemphigus (PNP)
characteristically immunoprecipitate five proteins,
observations confirmed with the sera examined in this
study. The proteins characterized thus far as auto-
antigens in PNP all belong to the plakin family of
proteins and include desmoplakin, the 230 kDa bullous
pemphigoid antigen, and envoplakin. The pattern of
bands precipitated from metabolically labeled human
keratinocyte extracts by each PNP serum was different,
suggesting varying titers of antibodies against unique
epitopes in various plakin family members. To further
characterize this PNP antibody response, we produced
fusion proteins of the homologous tail region of five
plakin family members, including the recently cloned
periplakin. Immunoblotting of equal amounts of each
Paraneoplastic pemphigus (PNP) is a newly characterizedautoimmune blistering skin disease associated withthymoma and lymphoproliferative disorders, such as non-Hodgkin’s lymphoma, Castleman’s disease, and chroniclymphocytic leukemia (Anhalt et al, 1990; Anhalt, 1997).
In PNP, patients with these tumors develop a severe erosive oral
gingivostomatitis and a blistering skin rash resembling erythema multi-
forme. Histology of the skin and mucous membrane lesions demon-
strates two basic patterns. One is suprabasilar acantholysis, as seen in
pemphigus vulgaris. The other is an interface dermatitis with basal cell
vacuolar changes and individual keratinocyte dyskeratosis, similar to
the histology of erythema multiforme (Horn and Anhalt, 1992). Direct
immunofluorescence may show IgG and/or the third component of
complement deposited on the keratinocyte cell surface or on the
epidermal basement membrane zone (Anhalt et al, 1990; Fullerton et al,
1992; Lam et al, 1992). Indirect immunofluorescence shows that PNP
patients have serum antibodies that bind to the surface of cells not
only in stratified squamous epithelia, similar to pemphigus vulgaris
antibodies, but also in transitional, columnar, and simple epithelia as
well as to other nonepithelial desmosomal containing tissues (Anhalt
et al, 1990; Helou et al, 1995). Immunoelectron microscopy has shown
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plakin tail-glutathione S-transferase fusion protein with
PNP sera revealed a strong reaction with the envoplakin
tail domain. Each sera also recognized periplakin, and
certain sera recognized desmoplakin and plectin, and,
weakly, bullous pemphigoid antigen 1. PNP sera were
affinity purified with periplakin and envoplakin tail fusion
proteins. Immunoprecipitation and immunoblotting
with these affinity purified antibodies revealed shared as
well as unique epitopes in the tail domains of these
plakins. This study indicates that a homologous
region in the carboxy-terminus of plakins, including
the newly characterized periplakin, serves as an antigenic
site in PNP. Key words: bullous pemphigoid antigen/
desmoplakin/envoplakin/plectin. J Invest Dermatol 111:308–
313, 1998
that the PNP antigens are components of hemidesmosomes and
desmosomes and may spread beyond the desmosomes along the
keratinocyte cell surface (Joly et al, 1994).
PNP antibodies precipitate a characteristic complex of polypeptides
of approximate molecular weights 250, 230, 210, 190, and 170 kDa
from extracts of cultured human keratinocytes (Anhalt et al, 1990;
Oursler et al, 1992). Three of these polypeptides have been identified
as desmoplakin I, 250 kDa, bullous pemphigoid antigen 1 (BPAG1),
230 kDa, and envoplakin, 210 kDa (Hashimoto et al, 1995; Kim et al,
1997). Some PNP sera also recognize desmoplakin II that migrates on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
slightly slower than envoplakin (Oursler et al, 1992; Hashimoto et al,
1995). Interestingly, all of these molecules that have been identified
are members of the plakin gene family (Green et al, 1992; Ruhrberg
et al, 1996).
Plakins are molecules that associate with cytokeratins, and are
thought to link the keratin intermediate filaments to the cell surface,
specifically to desmosomes and hemidesmosomes (Ruhrberg and Watt,
1997). In the desmosomes the two known plakins are desmoplakin
(Green and Jones, 1996) and envoplakin (Ruhrberg et al, 1996),
whereas BPAG1 (Green and Jones, 1996) and plectin (Foisner and
Wiche, 1991; Uitto et al, 1996) are associated with hemidesmosomes;
however, there is evidence that plectin is not confined to hemidesmo-
somes and that it is also associated with desmosomes (Eger et al, 1997).
The common structure shared by plakins is an amino-terminal globular
domain, a central coiled-coil rod domain, and a carboxy-terminal tail
containing characteristic repeating amino acid domains (Green et al,
1992; Ruhrberg et al, 1996). These domains have been labeled as types
A, B, or C depending on the amount of homology (Green et al, 1992).
The number and types of the carboxy-terminal repeats are different in
each plakin family member.
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Originally identified along with envoplakin as a precursor to the
cornified envelope (Simon and Green, 1984), periplakin, a new
member of the plakin family, was recently characterized by cDNA
cloning and immunologic studies (Ruhrberg et al, 1997; Aho et al,
1998). Periplakin has also been localized to the desmosomes (Ruhrberg
et al, 1997). The deduced amino acid structure revealed a protein with
a calculated mass of 204 kDa and with a domain structure resembling
other plakin proteins. Periplakin has the shortest tail domain among
the plakins because it is lacking the A, B, and C domains; however,
its tail is homologous to the region preceding the C domain in other
plakin proteins. Because it is a plakin, like other PNP antigens, and
because it has a molecular weight of µ190 kDa, the size of one of the
polypeptides immunoprecipitated with PNP sera, we hypothesized
that periplakin is one of the PNP antigens. In this study we characterized
the PNP antibody response against periplakin and compared it with
the response against other plakins.
MATERIALS AND METHODS
Sera PNP sera were kindly provided by Drs. Richard Sontheimer (PNP899),
Lois Matsuoka (PNP906), and Grant Anhalt (PNP1081, PNP1341, PNP3021,
and PNP3023).
Immunoprecipitation Metabolic labeling of human keratinocytes and
immunoprecipitation were performed as previously described (Stanley et al,
1984). Primary human keratinocytes from neonatal foreskin were propagated,
without feeders and without fetal calf serum, in complete MCDB 153 medium
(Sigma, St. Louis, MO) containing 30 µM calcium and bovine pituitary extract,
insulin, epidermal growth factor, hydrocortisone, and nonessential amino acids
as described in detail by Ando and Jensen (1996). Cells were grown to confluency,
washed three times with methionine- and cysteine-deficient Dulbecco’s minimal
essential medium (Gibco BRL, Grand Island, NY), and incubated overnight
with 1 mCi 35S- methionine and cysteine (Amersham, Arlington Heights, IL)
in 3 ml methionine- and cysteine-deficient Dulbecco’s minimal essential medium
containing 10% fetal bovine serum (Gibco BRL), penicillin/streptomycin
(Gibco BRL), and 1 mM CaCl2. Cells were washed three times with phosphate
buffered saline (PBS; Gibco BRL) and extracted in lysis buffer containing
10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, 10 µg aprotinin per
ml, 10 µg leupeptin per ml, and 1 mM phenylmethylsulfonyl fluoride. The cell
lysate was vortexed for 30 s then centrifuged at 16,000 rpm for 10 min. Bovine
serum albumin (BSA; Sigma) was added to the supernatant at a final concentration
of 0.1%.
The labeled cell extract was precleared with normal human serum for 2 h at
4°C and antibodies were precipitated with protein A-bearing staphylococci
(Pansorbin; Calbiochem, La Jolla, CA). Human PNP anti-sera (1–5 µl) or
affinity purified antibodies (0.2–100 µg) were added to 107 cpm of the precleared
extract, then incubated overnight at 4°C. Antibodies were precipitated with
Pansorbin that was then washed three times each with DEThi/BSA (10 mM
Tris, pH 7.4, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.5 M NaCl,
0.2% NaN3 and 0.1% BSA), DEThi (no BSA), and TBS (10 mM Tris, pH 7.4
and 150 mM NaCl). The final pellet was re-suspended in Laemmli buffer (Bio-
Rad Laboratories, Hercules, CA) and heated at 100°C for 5 min. The labeled
proteins in the supernatant were separated by 6% SDS-PAGE and then visualized
by autoradiography.
Immunoprecipitation experiments were also carried out using biotin-labeled
keratinocyte proteins with the Cellular Labeling and Immunoprecipitation Kit
(Boehringer, Mannheim, Germany). Confluent cultured human keratinocytes
were incubated with 1 mM CaCl2 for 2 d. The cells were then washed
extensively with ice-cold PBS and lysed in biotinylation lysis buffer (50 mM
sodium borate, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 10 µg aprotinin per ml, 10 µg leupeptin per ml, and 1 mM
phenylmethylsulfonyl fluoride). Cells were then scraped into microfuge tubes,
vortexed for 30 s, incubated on ice for 15 min, and then centrifuged at
16,000 rpm for 10 min. The supernatant was collected and total cellular proteins
were biotinylated on ice for 15 min with 0.25 mg D-biotinoyl-ε-aminocaproic
acid-N-hydroxy succanimide ester per ml. The reaction was stopped with
50 mM NH4Cl. The remaining immunoprecipitation steps were as described
above.
The precipitated biotinylated proteins were separated by 6% SDS-PAGE and
transferred to nitrocellulose membranes (Trans-Blot, Bio-Rad Laboratories,
Hercules, CA). Membranes were incubated for 1 h each with blocking solution
(PBS, 0.05% Tween-20, 1% BSA, and 1% normal goat serum) and then with
streptavidin-horseradish peroxidase conjugate in blocking solution. After three
quick rinses followed by five rinses over the course of 30 min with washing
solution (PBS 1 0.05% Tween-20), the blots were developed for chemi-
luminescence by ECL (Amersham).
Molecular cloning, production, and purification of plakin fusion
proteins Homologous regions within the tail domains of periplakin, envo-
plakin, plectin, desmoplakin, and BPAG1 were cloned by polymerase chain
reaction from a human keratinocyte matchmaker cDNA library (Clontech
Laboratories, Palo Alto, CA). Primers were: periplakin, forward 59AGAATT-
CAAGCGGGAGCAGCGGGAG39 and reverse 59AGTCGACCTTCTGC-
CCAGATACCAAGA39 (Genbank accession #AF13717); envoplakin, forward
59AGAATTCGAGACCCAGACGCGAGAG39 and reverse 59 AGTCGA-
CGGTCTCCCCAGCTACAAGC39 (Genbank accession #U53786); plectin,
forward 59AGAATTCAAGACGTCCTCCAAGTCCTC39 and reverse 59AG-
TCGACGGCGTTGCCCGAGAGCAT39 (Genbank accession #U53204);
desmoplakin, forward 59AGAATTCCAGACATCACAAAAGAATACCC39
and reverse 59AGTCGACCTGCACCAAGGAGATCATG39 (Genbank acces-
sion #J05211); BPAG1, forward 59AGAATTCAACATTTCCAATCTCA-
ATGTCAA39 and reverse 59AGTCGACTAACCGGCTCAGCAAAGAATC39
(Genbank accession #M63618). The polymerase chain reaction products were
digested with EcoRI and SalI and ligated into pGEX-4T-1 (Pharmacia,
Piscataway, NJ). Glutathione-S-transferase (GST)-fusion proteins consisting
of either the 111 or the 112 amino acid conserved region of the tail domains
of envoplakin, periplakin, desmoplakin, plectin, and BPAG1 were expressed in
Escherichia coli XL1-Blue cells (Stratagene, La Jolla, CA). The fusion proteins
were purified over a glutathione Sepharose 4B column according to the
manufacturer’s protocol (Pharmacia). Envoplakin-GST and periplakin-GST
were used to affinity purify the PNP serum #3023. As a negative control, a
GST-fusion protein with mouse type XVII collagen α1 chain domain 16 A
(COL17-GST) was used (a kind gift from Dr. Kehua Li).
Affinity purification and adsorption of PNP antibodies with plakin
fusion proteins PNP3023 serum was affinity purified on envoplakin-GST,
periplakin-GST, and, as a control, COL17-GST columns. The fusion proteins
(1.5 mg) were N-cross linked to CM Affi-Gel-10 column (1 ml) (Bio-Rad
Laboratories) overnight at 4°C in 100 mM MOPS (pH 7.5) (periplakin-GST)
or 100 mM MOPS (pH 7.5) 1 80 mM CaCl2 (envoplakin-GST and COL17-
GST). The gel matrix was washed with 10 column volumes each of 10 mM
Tris (pH 7.5), 10 mM Tris (pH 7.5) 1 0.5 M NaCl, and 10 mM Tris
(pH 2.5) 1 100 mM glycine 1 0.5 M NaCl and re-equilibrated with 20 ml
of 10 mM Tris (pH 7.5). PNP3023 serum (5 ml) was diluted with 15 ml of
10 mM Tris (pH 7.5) and run through the gel matrix three times. The column
was subsequently washed with 20 column volumes each of 10 mM Tris (pH 7.5)
and 10 mM Tris (pH 7.5) 1 0.5 M NaCl. Bound antibodies were eluted in
18 ml of 10 mM Tris (pH 2.5) 1 100 mM glycine 1 0.5 M NaCl into a tube
containing 2 ml of 1 M Tris (pH 7.5). Eluted antibodies were dialyzed overnight
against PBS (2 liters) at 4°C, concentrated by Centricon-10 (Amicon, Lexington,
MA), then BSA was added to a final concentration of 0.1%.
Immunoblotting GST, COL17-GST, BPAG1-GST, plectin-GST, desmo-
plakin-GST, periplakin-GST, and envoplakin-GST were resolved by 14% SDS-
PAGE (Novex, San Diego, CA) and transferred to nitrocellulose membrane
(Trans-Blot, Bio-Rad Laboratories). Membranes were incubated with blocking
solution (PBS, 0.05% Tween-20, 4% dry milk, 1% BSA, and 1% normal goat
serum) for 1 h at room temperature. Membranes were probed at 4°C overnight
with primary anti-sera, PNP899 (1:1000), PNP906 (1:1000), PNP3021 (1:1000),
or antibodies from PNP sera affinity purified on COL17-GST (0.2 µg per ml),
envoplakin-GST (0.3 µg per ml), and periplakin-GST (0.8 µg per ml). After
three quick rinses followed by five rinses over the course of 30 min with
washing solution (PBS 1 0.05% Tween-20), membranes were probed with
horseradish peroxidase-conjugated goat anti-human IgG (1:2000, Bio-Rad
Laboratories) for 1 h at room temperature and developed for chemiluminescence
by ECL (Amersham).
RESULTS
PNP sera bind to a homologous region within the carboxy-
terminus of members of the plakin gene family, including
periplakin PNP sera immunoprecipitated multiple polypeptides
from extracts of human keratinocytes (Fig 1). Several of these poly-
peptides have been identified as PNP antigens, including desmoplakin
I (250 kDa), BPAG1 (230 kDa), and envoplakin (210 kDa), all members
of the plakin family of proteins (Anhalt, 1997; Ruhrberg and Watt,
1997). The unidentified 190 kDa band could be the newly cloned
periplakin, also a member of the plakin family; however, it has been
suggested that envoplakin and periplakin form heterodimers (Ruhrberg
et al, 1997), therefore periplakin may be simply coprecipitated with
envoplakin and may not be an antigen per se. As shown in Fig 1,
however, the 210 and the 190 kDa polypeptides are not always
precipitated in the same stoichiometric ratio by various PNP sera
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(Fig 1, lanes PNP906, PNP1081, and PNP3021). Therefore, we
hypothesized that each polypeptide contains an epitope recognized by
PNP antibodies, and that these epitopes might be in the homologous
regions of these various plakin molecules.
Periplakin protein contains only a short carboxy-terminal globular
domain and does not contain the A, B, or C repeats found within the
carboxy-terminal domains of other plakin family members (Fig 2A).
The computer alignment of the amino acid sequences of these tail
regions showed highest homology within the region immediately
before the C repeat of each plakin family protein (Fig 2B). The
homology domain of each protein, also referred to as the linker region
by Ruhrberg et al (1997), was cloned as a GST-fusion protein and
expressed in bacteria (Fig 2A). The fusion proteins were affinity
purified on glutathione-Sepharose 4B columns, then separated by
SDS-PAGE. Coomassie Blue staining of these gels showed purified
GST-fusion proteins of the expected molecular sizes (see Fig 6A).
The GST-fusion proteins were then used to analyze, by immuno-
blotting, five PNP sera, and data for four of these sera are shown in
Fig 3 and for one of these sera (PNP3023) in Fig 6(B). All five PNP
sera detected the periplakin-GST and envoplakin-GST fusion proteins.
PNP906 bound only to these two fusion proteins. Three PNP sera
Figure 1. PNP sera precipitate plakin proteins in different
stoichiometric ratios. Immunoprecipitation with two normal human sera
(NHS) and six different PNP sera (PNP899, PNP906, PNP1081, PNP1341,
PNP3021, and PNP3023) of metabolically labeled human keratinocyte cell
lysates. Five specifically precipitated proteins of Mr 250 (DP, desmoplakin), 230
(BPAG1, bullous pemphoid antigen 1), 210 (EV, envoplakin), 190, and 170 kDa
are marked. Molecular weight markers on the left are 202 and 116 kDa.
Figure 2. Conserved regions in the
carboxy-terminus of plakin proteins. (A)
Homologous regions within the tail domain of
five plakin proteins. The hatched boxes
represent the 111/112 amino acid region of
highest homology. PP, periplakin; EV,
envoplakin; DP, desmoplakin; PL, plectin;
BPAG1, bullous pemphigoid antigen 1. (B)
Alignment of the amino acids encoded by the
hatched boxes in (A). Conserved amino acids
are boxed.
(PNP899, PNP1081, and PNP3023) also bound the desmoplakin-
GST fusion protein and, surprisingly, two sera (PNP899 and PNP1081)
bound strongly and one sera (PNP3021) bound weakly to the plectin-
GST fusion protein. Binding to the plectin fusion protein was unexpec-
ted because plectin has not been identified in immunoprecipitates of
keratinocyte extracts with PNP sera. Finally, two sera (PNP899 and
PNP3021) bound weakly to the BPAG1-GST fusion protein. None
of the sera bound to GST alone. Normal human serum did not bind
to any of these fusion proteins (data not shown).
These data indicated that PNP sera recognize homologous regions
in the carboxy-terminal tails of plakin proteins, including that of the
newly cloned periplakin, and confirm a recent report in which IgG
from a PNP serum was shown to bind the carboxy-terminal region
(containing the homologous domain used in our fusion proteins) of
envoplakin (Kim et al, 1997).
PNP antibodies recognize shared as well as unique epitopes on
periplakin and envoplakin We affinity purified PNP3023 serum
on either envoplakin-GST or periplakin-GST and used the affinity
purified antibodies to immunoprecipitate extracts of human keratino-
cytes that were labeled either by 35S-methionine/cysteine or by
biotinylation. Figure 4 shows that both affinity purified antibodies
precipitated the 190 and 210 kDa molecules but with different
stoichiometry. Comparison with the intensity of the periplakin band
shows that anti-envoplakin-GST antibodies precipitated relatively more
envoplakin compared with anti-periplakin-GST antibodies. These data
suggest that either envoplakin and periplakin tail domains contain both
shared and unique epitopes, or that there are only unique epitopes but
coprecipitation of a complex of envoplakin and periplakin brings down
both proteins as suggested by Ruhrberg et al (1997).
To further investigate these possibilities we performed immuno-
blotting of envoplakin-GST and periplakin-GST with PNP sera,
unadsorbed or adsorbed with envoplakin-GST or periplakin-GST
(Fig 5). PNP899 and PNP906 sera both bound to envoplakin-GST
and periplakin-GST; however, envoplakin-GST adsorbed out from
PNP899 antibodies binding to both envoplakin-GST (as expected) and
periplakin-GST, demonstrating that the antibodies against envoplakin
cross-reacted with periplakin (i.e., shared epitopes). On the other hand,
adsorption of PNP906 serum with envoplakin-GST did not adsorb
out staining against periplakin-GST and adsorption with periplakin-
GST did not adsorb out staining against envoplakin-GST, demonstrating
that this serum has antibodies against unique epitopes on both envo-
plakin and periplakin.
Additional experiments were performed with PNP3023 serum
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Figure 3. PNP sera recognize plakin tail-GST fusion proteins. Western
blot of recombinant GST-fusion proteins of the conserved region within the
tail domains of periplakin, envoplakin, plectin, desmoplakin, and BPAG1
(hatched boxes, Fig 2A) with four different paraneoplastic pemphigus sera
(PNP899, PNP906, PNP1081, and PNP3021).
affinity purified on envoplakin-GST or periplakin-GST columns or as
a control on a COL17-GST column. The unpurified serum bound
very strongly to envoplakin-GST on immunoblots, less strongly to
periplakin-GST, and very weakly to desmoplakin-GST (Fig 6B). No
specific antibody was affinity purified on COL17-GST (Fig 6C). Flow
through from the COL17-GST column bound these fusion proteins,
as did whole serum (Fig 6D). Affinity purified antibodies against
envoplakin-GST bound very strongly to envoplakin-GST and weakly
to periplakin-GST and desmoplakin-GST, demonstrating antibodies
against shared epitopes (Fig 6E). Flow through from the envoplakin-
GST column bound only periplakin-GST (Fig 6F), demonstrating
unique epitopes on periplakin not found on envoplakin. Antibodies
affinity purified on periplakin-GST bound both periplakin-GST and
envoplakin-GST (Fig 6G), showing shared epitopes. Flow through
from the periplakin-GST column bound only to envoplakin-GST
(Fig 6H), demonstrating epitopes on envoplakin not found on
periplakin.
Figure 4. PNP serum affinity purified on envoplakin and periplakin
fusion proteins immunoprecipitate the 210 and 190 kDa polypeptides
with different stoichiometry. Metabolically labeled (A) or biotin labeled (B)
keratinocyte cell lysates were immunoprecipitated by antibodies affinity purified
with COL17-GST (1.6 µg; lane 1), envoplakin-GST (0.5 µg; lane 2), and
periplakin-GST (5 µg; lane 3) fusion proteins. Note that the ratio of the
210 kDa envoplakin to the 190 kDa periplakin is greater with antibodies
affinity purified on envoplakin-GST compared with those affinity purified on
periplakin-GST.
Figure 5. PNP sera contain antibodies that recognize common as well
as unique epitopes between envoplakin and periplakin. Western blot of
envoplakin-GST and periplakin-GST fusion proteins with two different PNP
sera, PNP899 and PNP906. The primary antibodies were incubated in the
presence of excess exogenous envoplakin-GST (10 µg per ml) or periplakin-
GST (10 µg per ml) fusion proteins.
The flow through from the envoplakin-GST, periplakin-GST, and
COL17-GST columns were also used for immunoprecipitation of
keratinocyte extracts (data not shown). All these flow through antibodies
precipitated envoplakin, periplakin, and desmoplakin with the same
stoichiometry, suggesting that the tail domains of envoplakin and
periplakin do not contain all the epitopes bound by PNP serum in the
full length molecules.
Taken together, these results demonstrate that PNP sera have
antibodies against unique as well as shared epitopes on periplakin and
envoplakin.
DISCUSSION
In this report we have identified a novel plakin family member as an
autoantigen in paraneoplastic pemphigus patients. Thus far the following
plakins have been identified as PNP autoantigens: desmoplakin I,
desmoplakin II, BPAG1, envoplakin, and, in this report, periplakin.
These are not simply coprecipitated by an antibody against one of
them, because not all periplakin sera precipitate all these molecules
and the stoichiometry of precipitation varies among different PNP
sera. In addition, we demonstrate, as have others (Oursler et al, 1992;
Hashimoto et al, 1995; Kim et al, 1997), that antibodies from PNP
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Figure 6. Affinity purification of antibodies against envoplakin-GST
and periplakin-GST from PNP serum. PNP3023 was used to affinity purify
antibodies against COL17-GST (C and D), envoplakin-GST (E and F), and
periplakin-GST (G and H). The flow through (D, F, and H) as well as the
bound (C, E, and G) antibodies were collected and subjected to immunoblot
analysis. (A) Coomassie Blue staining of the SDS-PAGE gel to show equal
loading of the GST-fusion proteins (1 µg per lane). Molecular weight markers
to the left are 40 and 29 kDa. (B) Immunoblot of the proteins shown in (A)
with PNP3023 serum.
sera bind to the individual plakins. We show here that these antibodies
recognize both shared epitopes in homologous regions of the carboxy-
terminus of these plakins as well as unique epitopes in each plakin. In
addition, PNP antibodies bind to the homologous region of plectin,
which has not been implicated to date in PNP. The significance of
this finding is not clear as plectin has not been demonstrated in
immunoprecipitates of keratinocyte extracts with PNP sera. It may be
that immunoprecipitated plectin is difficult to demonstrate on SDS-
PAGE due to its high molecular weight (µ600 kDa), or it may be
that antibodies bind the denatured plectin-GST on immunoblot but
do not bind to the native plectin in immunoprecipitation assays.
Plakins are a family of proteins that are thought to link desmosomal
and hemidesmosomal proteins to intermediate filaments in order to
maintain structural integrity of the cell. A new member of the plakin
family, periplakin, was recently cloned by two independent groups
(Ruhrberg et al, 1997; Aho et al, 1998). Specifically, cDNA cloning
allowed identification of a contiguous reading frame encoding a
putative polypeptide of µ204 kDa. Northern and multiple tissue RNA
analysis revealed that periplakin is expressed in keratinocytes and in
other tissues with prominent epithelial components (Aho et al, 1998).
By indirect immunofluorescence, periplakin was found expressed in
all cell layers of human epidermis, but more strongly in the upper
spinous and granular layers (Ruhrberg et al, 1997). Periplakin was also
found expressed in other stratified squamous epithelia such as oral,
cervical, and esophageal mucosa. The expression pattern of periplakin
is similar to that of envoplakin in all tissues with the exception of
esophagus, where envoplakin was expressed only in the outermost
layers, whereas periplakin was expressed in all cell layers. Immuno-
electron microscopy suggested that periplakin is a component of
desmosomes within epidermal keratinocytes (Ruhrberg et al, 1997).
Chromosomal assignment by radiation hybrid mapping placed the
human periplakin gene to chromosomal region 16p13 (Aho et al,
1998). No human genetic disease has been mapped as yet to the
periplakin gene locus; however, periplakin clearly serves as an
autoantigen in PNP.
Exactly why patients with PNP develop antibodies to periplakin and
related molecules and whether any of these antibodies are pathogenic is
currently not known. It has been speculated that the types of tumors
associated with PNP may produce plakins that result in an immune
response (Anhalt, 1997). This is similar to what is thought to happen
in patients with some ovarian carcinomas that result in ataxia due to
an immune response against Purkinje cells in the cerebellum (Brashear
et al, 1989; Furneaux et al, 1990) and in patients with some oat cell
carcinomas who develop retinopathy due to an immune response
against tumor antigens also found in retina (Grunwald et al, 1987;
Thirkill et al, 1989); however, tumors of PNP patients have not been
carefully examined for plakin production.
Because plakins are located inside cells it is not likely that the anti-
plakin PNP antibodies initiate pathology in PNP; however, it has
recently been shown that anti-desmoplakin antibodies may perpetuate
pathology in erythema multiforme (Foedinger et al, 1995). Because
histology of PNP lesions may resemble that of erythema multiforme
(Horn and Anhalt, 1992), the anti-plakin PNP antibodies might
contribute to the pathology.
We would speculate, however, that the pathology is probably
initiated by antibodies against either the unidentified 170 kDa PNP
antigen or desmoglein 3 (pemphigus vulgaris antigen) (Joly et al, 1994).
Further studies will be necessary to sort out how the immune response
is triggered and how the antibodies contribute to the pathophysiology
of disease.
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